ASCO26: Bispecific antibody and RET fusion-targeting assets garner attention in NSCLC

ConferenceMixedHarmoni-6RetvemoPositive

AI Analysis

Summary

At ASCO26, Summit's Harmoni-6 bispecific antibody data received mixed feedback, while Eli Lilly's RET fusion-targeting drug Retvemo showed positive results that expanded its potential use in adjuvant NSCLC.

Outcome Details

Summit's Harmoni-6 results drew a mixed reaction; Eli Lilly's Retvemo data was positive and expanded its potential in adjuvant NSCLC

Importance:6/10

Sentiment:

0.30

ASCO26bispecific antibodyRET fusion-targetingNSCLCadjuvant setting

Related Companies

$SMMT $LLY

Read the original article

Published by Pharmaceutical Technology on June 2, 2026 11:44 PM

Read Original